Načítá se...

Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy

BACKGROUND: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years. METHODS: One hundred seventy-two consecutive eyes of 163 prospective treatment-naïve patients with PCV w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Ophthalmol
Hlavní autor: Hikichi, Taiichi
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4393615/
https://ncbi.nlm.nih.gov/pubmed/25881324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-015-0026-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!